Key Highlights
- A Phase 3 leukemia study sent SELLAS Life Sciences up 163.69% to USD 19.70 in Tuesday trading on November 17, 2026, with treated patients living a median 24.0 months and the control group 14.7 months.
- Declines of 51.45% at Cue Biopharma (USD 6.85) and 47.45% at Scilex Holding (USD 0.66) came without any company release dated between November 14 and November 17, based on a search.
- Two smaller names also advanced, Cingulate by 24.53% to USD 4.67 and Gain Therapeutics by 23.38% to USD 1.16, though neither had company news on November 17.
- Funding frames each story. SELLAS holds the most cash, USD 134.7 million, ahead of Cue at USD 57.9 million, Cingulate at USD 23.2 million and Gain at USD 11.70 million, while Scilex reports just USD 0.6 million.
Cue Biopharma (NASDAQ:CUE): Shares Halve Without a Dated Announcement
On Tuesday, November 17, 2026, Cue Biopharma (NASDAQ:CUE) changed hands at USD 6.85, a 51.45% decline that implies a prior close near USD 14.11 (calculated and unverified). Searches of company releases turned up no trial update, financing notice or statement between November 14 and November 17, which leaves the cause unconfirmed. The Quarterly Report to September 30 shows the Balance Sheet strengthening, with cash up to USD 57.9 million from USD 27.1 million at the end of last year. The income statement tells a harsher tale: a third-quarter net loss of USD 50.0 million, compared with USD 7.4 million in the prior-year period. Nine-month losses of USD 208.3 million include roughly USD 90.0 million in non-cash Warrant charges and USD 59.4 million in stock-based pay. After a 1-for-30 reverse split on April 23, 2026, 8,359,523 shares were outstanding as of November 13. October brought first dosing in a Phase 1 CUE-401 trial, and early-stage programs at Cue Biopharma (NASDAQ:CUE) Fail often.
Scilex Holding (NASDAQ:SCLX): Only USD 0.6 Million of Cash Behind a 47.45% Slide
At USD 0.66, Scilex Holding (NASDAQ:SCLX) was down 47.45%, and nothing announced between November 14 and November 17 accounted for the fall. Its portfolio of pain products includes ZTlido, ELYXYB and GLOPERBA, and a second Phase 3 study of SP-102 for sciatica is under way. The most recent 10-Q, for the quarter that ended June 30, 2026, put cash at USD 0.6 million after USD 5.0 million at year-end, with a USD 115.0 million second-quarter net loss driven largely by Fair Value losses. Debts due within a year of USD 80.8 million and promissory notes of USD 2.2 million add to about USD 83.0 million (calculated); nothing is classed as noncurrent. A May 6, 2026 release outlined a USD 1.0 billion stock Acquisition agreement tied to the subsidiaries ACEA Therapeutics and ACEA Pharma, and closing was not verified. Scant Liquidity exposes Scilex Holding (NASDAQ:SCLX) to dilution, and quotes below USD 1 can reverse.
SELLAS Life Sciences (NASDAQ:SLS): Survival Data From a Phase 3 Trial Power a 163.69% Surge
SELLAS Life Sciences (NASDAQ:SLS) leapt 163.69% to USD 19.70, a move that implies a prior close near USD 7.47 (calculated), after a November 17, 2026 report that the pivotal REGAL trial reached its overall survival target in acute myeloid leukemia. The company's Vaccine galinpepimut-S, aimed at the WT1 protein, delivered a hazard ratio of 0.59, which equals 41% lower odds of death, as well as a p-value of 0.035. Median survival was 24.0 months for treated patients and 14.7 months for the comparison group. Enrolment stood at 126 patients, and the trial reached its prespecified 80 deaths. SELLAS holds USD 134.7 million in cash, plans to meet the FDA and aims to file a Biologics License Application in the first half of 2027. Applying USD 19.70 to 203.5 million shares gives about USD 4.0 billion (calculated), so the screener's market cap was dropped as inconsistent. Open-label design, a p-value barely under 0.05 and a small sample remain the key uncertainties for SELLAS Life Sciences (NASDAQ:SLS).
Cingulate (NASDAQ:CING): A 24.53% Rise With No Same-Day Trigger
Searches found no November 17 announcement behind the 24.53% rise in Cingulate (NASDAQ:CING), now at USD 4.67. The latest company news was its third-quarter report on November 13, 2026, and published coverage reported a 12.8% fall in the shares on that day, so some of the gain may be a rebound; that is an inference and not a reported cause. On June 1, 2026, the FDA sent back a complete response letter covering CTx-1301, the company's ADHD tablet. The letter raised chemistry, Manufacturing and controls requests but, according to the company, no clinical safety or efficacy concerns. Resubmission is expected sometime from December 2026 to January 2027, and the FDA targets two months for a Class 1 filing or six for Class 2. The third-quarter net loss was USD 7.7 million, and cash was about USD 23.2 million. Holders of Cingulate (NASDAQ:CING) face dilution from its at-the-market and Lincoln Park funding programs.
Gain Therapeutics (NASDAQ:GANX): A 23.38% Climb Set Against a Later Rexaceract Start
Neither a press release nor a filing dated November 17 explained why Gain Therapeutics (NASDAQ:GANX) rose 23.38% to USD 1.16. Its November 10, 2026 release showed a narrower third-quarter net loss, USD 3.16 million versus USD 5.28 million, alongside lower cash of USD 11.70 million against USD 20.84 million at year-end. Timing has also slipped: the Phase 2 trial of rexaceract, the Parkinson's candidate, is now expected to begin in the first quarter of 2027, where a June release had said the third quarter of 2026. Phase 1b results came from just 12 evaluable participants in an open-label extension. Cash on hand equals roughly 3.7 quarters of the latest loss (calculated, not company guidance), a funding risk for Gain Therapeutics (NASDAQ:GANX). With Market Value near USD 51 million (calculated), a handful of trades can move the price.
Where Things Stand
Just one of the five has a verified trigger. Positive Phase 3 data lifted SELLAS Life Sciences (NASDAQ:SLS), with an FDA meeting, secondary analyses and possible financing still to come. The slide at Cue Biopharma (NASDAQ:CUE) is unexplained. So is the one at Scilex Holding (NASDAQ:SCLX), where a company filing or release about the trading would be the first marker. Cingulate (NASDAQ:CING) rose without company news. Gain Therapeutics (NASDAQ:GANX) did too, and both face funding questions along with regulatory or trial milestones. Moves in small stocks can reverse once Volume settles.
_11_17_2026_18_59_44_560836.jpg)





Please wait processing your request...